Turn Therapeutics' Third-Quarter Net Loss Widens to $6.2 Million

Turn Therapeutics Inc.'s third-quarter net loss widened to $6.2 million from $1.9 million a year earlier, as the clinical-stage biotechnology company awaits an atopic dermatitis trial readout in 2027. For the three months ended Sept. 30, the company recorded a GAAP loss of $0.21 per basic and diluted share, compared with $0.07 per basic and diluted share in the third quarter of 2025. Research and development expenses rose to $605,197 from $158,699 a year earlier. General and administrative expenses declined to $1.4 million from $1.8 million over the same period. Turn Therapeutics held $10.4 million in cash and cash equivalents at Sept. 30. The company expects its available cash to fund operations into the third quarter of 2027.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.